Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Lantheus Holdings, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
Prev close 100.67 · gapped below the open, then crossed back over prior close. High/low 100.75 at 4:00 pm ET, 100.29 at 9:30 am ET.
Lantheus Holdings, Inc. has 9 disclosed suppliers and 2 disclosed customers. Each one is named in an SEC filing, either Lantheus Holdings, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Jubilant HollisterStier ("JHS") is currently a significant supplier of DEFINITY.”
FILING10-K0001193125-26-073498cik 0001521036
“Under the terms of the PNT2003 License Agreement, we paid POINT an upfront payment of $10.0 million, and could pay up to an additional $34.5 million in milestone payments upon the achievement of specified U.S. and ex-U.S. regulatory milestones.”
FILING10-K0001193125-26-073498cik 0001521036
“On September 24, 2025, we announced an exclusive licensing agreement for GE HealthCare Limited ("GE Healthcare") to develop, manufacture, and commercialize Lantheus' piflufolastat F-18 PET imaging agent (marketed in the United States as PYLARIFY) in Japan for prostate cancer diagnostics and companion diagnostic use.”
FILING10-K0001193125-26-073498cik 0001521036
“On June 18, 2024, we acquired Meilleur, including its asset NAV-4694, an investigational late-stage F-18-labeled PET imaging agent that targets beta amyloids in Alzheimer's disease.”
FILING10-K0001193125-26-073498cik 0001521036
“On June 15, 2024, we entered into an agreement with Radiopharm Theranostics Limited ("Radiopharm") to acquire all of Radiopharm's rights to two licensed preclinical assets for an upfront payment of $2.0 million (the "Radiopharm Asset Purchase").”
FILING10-K0001193125-26-073498cik 0001521036
“Internationally, we previously licensed exclusive rights to Curium Pharma ("Curium") to develop and commercialize piflufolastat F-18 in Europe, where it is being commercialized in the European Union under the brand name PYLCLARI.”
FILING10-K0001193125-26-073498cik 0001521036
“Previously, on July 3, 2024,we acquired from Life Molecular the global rights to RM2, its clinical stage, gastrin-releasing peptide receptor ("GRPR")-targeting agent, including the associated novel, clinical-stage radiotherapeutic and radiodiagnostic pair, previously referred to as 177Lu-DOTA-RM2 and 68Ga-DOTA-RM2 (and which we now refer to as LNTH-2402 and LNTH-2401, respectively), for an upfront payment of $35.0 million plus a $1.0 million payment made prior to the acquisition (the "RM2 Asset Purchase"), pursuant to the Sublicense, Development and Collaboration Agreement, by and between us and Life Molecular, dated as of June 27, 2024 (the "RM2 Sublicense Agreement").”
FILING10-K0001193125-26-073498cik 0001521036
“On February 6, 2023, we acquired Cerveau and made an upfront payment of approximately $35.3 million to the Cerveau Stockholders.”
FILING10-K0001193125-26-073498cik 0001521036
“This category of revenues also includes royalties and other milestone payments received from our strategic partners that have commercialized products pursuant to license arrangements with us as well as CDMO revenue generated by Evergreen, which we acquired on April 1, 2025.”
FILING10-K0001193125-26-073498cik 0001521036
“In November 2025 and in accordance with the terms of the Sale and Purchase Agreement, we finalized the net working capital accounts with Life Medical and we received a $2.3 million payment from Life Medical.”
FILING10-K0001193125-26-073498cik 0001521036
“In May 2014 (as amended in June 2022), we entered into a license and collaboration agreement with Lantheus (formerly LMI and formerly Piramal Imaging SA) covering our Tau-PET Imaging tracers.”
FILING20-F0001104659-26-027342cik 0001651625disclosed by ACIU
Watchlist prices, news filtered to it, and its next report on your desk.
LNTH (Lantheus Holdings, Inc.) has 9 disclosed suppliers and 2 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: ACIU +0.44%, in healthcare.